Cargando…
Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells
Among herbal medicines, magnolia bark extract, particularly its components honokiol (Hono) and magnolol (Mag), has been widely documented to have antineoplastic properties. The present study aimed to evaluate the synergism of Hono and Mag in bladder cancer therapy both in vitro and in vivo. Treatmen...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677562/ https://www.ncbi.nlm.nih.gov/pubmed/33240083 http://dx.doi.org/10.3389/fphar.2020.549338 |
_version_ | 1783612001322270720 |
---|---|
author | Wang, Hisao-Hsien Chen, Ying Changchien, Chih-Ying Chang, Hsin-Han Lu, Pei-Jyun Mariadas, Heidi Cheng, Yu-Chen Wu, Sheng-Tang |
author_facet | Wang, Hisao-Hsien Chen, Ying Changchien, Chih-Ying Chang, Hsin-Han Lu, Pei-Jyun Mariadas, Heidi Cheng, Yu-Chen Wu, Sheng-Tang |
author_sort | Wang, Hisao-Hsien |
collection | PubMed |
description | Among herbal medicines, magnolia bark extract, particularly its components honokiol (Hono) and magnolol (Mag), has been widely documented to have antineoplastic properties. The present study aimed to evaluate the synergism of Hono and Mag in bladder cancer therapy both in vitro and in vivo. Treatment with Mag alone at concentrations up to 80 μM failed to have an antiproliferative effect. In contrast, the combination of Hono and Mag at 40 μM decreased viability, caused cell cycle arrest and enhanced the proportion of Annexin V/7AAD-positive cells. Moreover, Mag with Hono at 40 μM induced caspase 3-dependent apoptosis and autophagy. Neither Hono nor Mag alone had an anti-migratory effect on bladder cancer cells. In contrast, Hono and Mag at 20 μM inhibited the motility of TSGH8301 and T24 cells in wound-healing and Transwell assays. The above phenomena were further confirmed by decreased phosphorylated focal adhesion kinase (p-FAK), p-paxillin, integrin β1, and integrin β3 protein levels. In a nude mouse xenograft model, Mag/Hono administration preferentially retarded T24 tumor progression, which was consistent with the results of cellular experiments. Current findings suggest Hono and Mag treatment as a potential anticancer therapy for both low- and high-grade urothelial carcinoma. |
format | Online Article Text |
id | pubmed-7677562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76775622020-11-24 Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells Wang, Hisao-Hsien Chen, Ying Changchien, Chih-Ying Chang, Hsin-Han Lu, Pei-Jyun Mariadas, Heidi Cheng, Yu-Chen Wu, Sheng-Tang Front Pharmacol Pharmacology Among herbal medicines, magnolia bark extract, particularly its components honokiol (Hono) and magnolol (Mag), has been widely documented to have antineoplastic properties. The present study aimed to evaluate the synergism of Hono and Mag in bladder cancer therapy both in vitro and in vivo. Treatment with Mag alone at concentrations up to 80 μM failed to have an antiproliferative effect. In contrast, the combination of Hono and Mag at 40 μM decreased viability, caused cell cycle arrest and enhanced the proportion of Annexin V/7AAD-positive cells. Moreover, Mag with Hono at 40 μM induced caspase 3-dependent apoptosis and autophagy. Neither Hono nor Mag alone had an anti-migratory effect on bladder cancer cells. In contrast, Hono and Mag at 20 μM inhibited the motility of TSGH8301 and T24 cells in wound-healing and Transwell assays. The above phenomena were further confirmed by decreased phosphorylated focal adhesion kinase (p-FAK), p-paxillin, integrin β1, and integrin β3 protein levels. In a nude mouse xenograft model, Mag/Hono administration preferentially retarded T24 tumor progression, which was consistent with the results of cellular experiments. Current findings suggest Hono and Mag treatment as a potential anticancer therapy for both low- and high-grade urothelial carcinoma. Frontiers Media S.A. 2020-11-06 /pmc/articles/PMC7677562/ /pubmed/33240083 http://dx.doi.org/10.3389/fphar.2020.549338 Text en Copyright © 2020 Wang, Chen, Changchien, Chang, Lu, Mariadas, Cheng and Wu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Hisao-Hsien Chen, Ying Changchien, Chih-Ying Chang, Hsin-Han Lu, Pei-Jyun Mariadas, Heidi Cheng, Yu-Chen Wu, Sheng-Tang Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells |
title | Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells |
title_full | Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells |
title_fullStr | Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells |
title_full_unstemmed | Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells |
title_short | Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells |
title_sort | pharmaceutical evaluation of honokiol and magnolol on apoptosis and migration inhibition in human bladder cancer cells |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677562/ https://www.ncbi.nlm.nih.gov/pubmed/33240083 http://dx.doi.org/10.3389/fphar.2020.549338 |
work_keys_str_mv | AT wanghisaohsien pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells AT chenying pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells AT changchienchihying pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells AT changhsinhan pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells AT lupeijyun pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells AT mariadasheidi pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells AT chengyuchen pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells AT wushengtang pharmaceuticalevaluationofhonokiolandmagnololonapoptosisandmigrationinhibitioninhumanbladdercancercells |